Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDE-5 Inhibitors Add-on to Prostanoids in PAH
NCT00705588Phase 4Unknown
- Sponsor
- Rabin Medical Center
- Start
- Aug 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tadalafil and vardenafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Rabin Medical Center. Primary endpoints: Six Minute Walking Distance at 12 weeks and Pro-N-Terminal Brain Natriuretic Peptide at 12 weeks. Status: unknown.
02
Drugs
tadalafilvardenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00705588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705588.